Laboratory Studies Into the Pathology of Leukaemia
NCT03233763 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500
Last updated 2017-07-31
Summary
Ongoing laboratory work into the pathology of Leukaemia:
Conditions
Interventions
- PROCEDURE
-
Bone Marrow Aspirate
Diagnostic Bone Marrow aspirate
Sponsors & Collaborators
-
Royal Marsden NHS Foundation Trust
lead OTHER
Principal Investigators
-
David Taussig · Royal Marsden NHS Foundation Trust
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-04-24
- Primary Completion
- 2021-02-01
- Completion
- 2021-02-01
Countries
- United Kingdom
Study Locations
More Related Trials
-
B7.1/IL-2 Leukaemia Cell Vaccine for Non-Transplant AML RFUSIN2-AML2 (NTX)
NCT02493829 ·Status: UNKNOWN ·Phase: PHASE1
-
Evaluation of Splenic Irradiation in Chronic Lymphatic Leukemia
NCT02020109 ·Status: WITHDRAWN
-
Lentivirus Transduced Acute Myeloid Leukaemia Blasts Expressing B7.1 (CD80) and IL-2
NCT00718250 ·Status: UNKNOWN ·Phase: PHASE1
-
Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies
NCT05537766 ·Status: TERMINATED ·Phase: PHASE2
-
Extension Study to Evaluate Long-Term Effects of Luspatercept in Patients With Myelodysplastic Syndromes (MDS) (A536-05/MK-6143-003)
NCT02268383 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluate the Hematological Remission Rates and Survival Among Chinese Adult Patients With B-precursor ALL
NCT03123887 ·Status: COMPLETED
-
Study of Luspatercept for the Treatment of Anemia in Patients With Myelodysplastic Syndrome (MDS) (MK-6143-001)
NCT01749514 ·Status: COMPLETED ·Phase: PHASE2
-
A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands
NCT02546375 ·Status: COMPLETED
-
A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome
NCT01513317 ·Status: TERMINATED ·Phase: PHASE2
-
Efficacy and Safety Study of Recombinant Human Arginase 1 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT02899286 ·Status: UNKNOWN ·Phase: PHASE2
-
Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases
NCT00434447 ·Status: COMPLETED ·Phase: PHASE4
-
Biomarkers in Bone Marrow Samples From Young Patients With Acute Myeloid Leukemia
NCT01298414 ·Status: COMPLETED
-
Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia
NCT02914977 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD
NCT05137860 ·Status: UNKNOWN ·Phase: PHASE4
-
A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies
NCT00506402 ·Status: COMPLETED ·Phase: PHASE1
-
International Chronic Myeloid Leukemia Pediatric Study
NCT01281735 ·Status: RECRUITING
-
Biomarkers in Young Patients With Acute Myeloid Leukemia
NCT01138332 ·Status: COMPLETED
-
The Metabolic Syndrome Among Leukemia Survivors: Physiopathological Analysis
NCT02696304 ·Status: UNKNOWN ·Phase: NA
-
The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias
NCT05756322 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Assessment of Disease Burden in Hairy Cell Leukemia
NCT06781515 ·Status: RECRUITING ·Phase: NA
-
KRT-232 and TKI Study in Chronic Myeloid Leukemia
NCT04835584 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
An Open Label, Single Centre Mass Balance C14 Study in Patients With Acute Myeloid Leukaemia (AML)
NCT01019161 ·Status: COMPLETED ·Phase: PHASE1
-
Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL
NCT00330252 ·Status: COMPLETED ·Phase: PHASE1
-
Laboratory Study of Lymphoblasts in Young Patients With High-Risk Acute Lymphoblastic Leukemia
NCT00896766 ·Status: COMPLETED
-
Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma
NCT00532389 ·Status: COMPLETED ·Phase: PHASE1